Name of Trial/NCT#: 18F FES-PET/MRI for Tailoring Treatment of Luminal a and Lobular Breast Cancer (FESTA) (NCT05982496) Eligible patients: Women age ≥ 18 years with […]
Name of Trial/NCT#:Â Improving Detection and Outcomes in Patients With Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAPI PET Imaging (NCT07285993) Eligible patients: Women
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer (NCT05394259) Eligible patients:Â
Name of Trial: Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/​Advanced Invasive Lobular Breast Cancer (LBC) Eligible patients: Men and women age ≥ 18 yrs
Eligible patients: We are recruiting women who were recently diagnosed with metastatic (Stage IV) lobular breast cancer (either as a recurrence after breast cancer in
Eligible patients: Patients with biopsy-proven ER/PR-positive (defined as ER ≥1 percent and PR ≥1 percent by IHC) and HER2-negative advanced or metastatic LBC starting new
Biomarkers to Detect Endocrine Therapy Resistance/NCT06067503 Read More »
Name of Clinical Trial: A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer / NCT06557148 Eligible patients: Patients with estrogen receptor positive
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer Read More »
Name of Trial/NCT#: Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers / NCT05919108 Eligible patients: Individuals over 18 years of age newly diagnosed with
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers Read More »
Name of Trial: Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)/NCT05964504 Eligible patients: Patients with histologically confirmed metastatic (stage IV) lobular breast cancer, regardless
PLUMB Registry: Improving Survival for Metastatic Lobular Breast Cancer Read More »
Name of Trial: REPLOT: A Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic
REPLOT: Clinical Trial for Patients with Metastatic ILC Read More »
Name/Description of Trial: GALILEE: Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT / NCT05931302 Summary: Lobular breast cancer
Name of Trial/NCT#: LobularCard: Â NCT05410951 Summary: With this project we will aim to identify the frequency of 113 germline variants in lobular breast cancer patients.
LobularCard: Searching for Novel Germline Mutations in ILC Patients Read More »
Name of Clinical Trial: Fluciclovine F18 (Fluciclovine) and gallium Ga 68 (PSMA-11) PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer /
Name of Clinical Trial: 18F- fluoroestradiol (FES) PET/CT for Breast Cancer/NCT04883814 Summary: This phase 2 clinical trial is assessing the clinical value of using 18F-
Imaging Trial: 18F- fluoroestradiol (FES) PET/CT for Breast Cancer Read More »
Name of the Clinical Study: Understanding How CDH1 Germline Mutations Affect Hereditary Lobular Breast Cancer NCT04206891 Eligible patients: Patients who are under 45 years old
IEO TRIAL: CDH1 Genetic Screening in Lobular Breast Cancer Read More »
"*" indicates required fields